A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinoma Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Antineoplastic Agents, Phytogenic
  • Carcinoma, Non-Small-Cell Lung
  • Immunoconjugates
  • Lung Neoplasms
  • Taxoids

abstract

  • SGN-15 plus docetaxel is a well-tolerated and active second and third line treatment for NSCLC patients. Ongoing studies are exploring alternate schedules to maximize synergy between these agents.

publication date

  • October 2006

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3715069

Digital Object Identifier (DOI)

  • 10.1016/j.lungcan.2006.05.020

PubMed ID

  • 16934909

Additional Document Info

start page

  • 69

end page

  • 77

volume

  • 54

number

  • 1